

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/516,745	
Filing Date	December 4, 2004	
First Named Inventor	Florian LANG et al.	
Group Art Unit	Unknown 1647	
Examiner Name	Unknown	Ian Dang

Attorney Docket Number RUFF-3

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.D./	1	"The Merck Index, 13 <sup>th</sup> Edition" 2001, Merck & Co., INC., WHITEHOUSE STATION, NJ XP002267642.	
	2	"Phosphorylation of Nedd4-2 by Sgk1 regulates epithelial Na+ channel cell surface expression" Christophe Debonneville et al.; The EMBO Journal Vol. 20 No. 24 pp. 7052-7059, 2001.	
	3	"Evidence for an electrogenic, negatively protein-kinase-A-modulated, Na+-dependent HC0-3 transporter in human lymphocytes" L.A. de la Rose et al.; Pfluegers Arch -Eur J. Physiol (1999) 437:935-943.	
	4	Cellular Physiology and Biochemistry; Cell Physiol Biochem 2000; 10: 187-194 "The Shrinkage-activated Na+ Conductance of Rat Hepatocytes and its Possible Correlation to rENaC" Christoph Boehmer et al.	
	5	"Epithelial sodium channel regulated by aldosterone-induced protein sgk" Sei-Yu CHEN et al.; Proc. Natl. Acad Sci, USA vol. 96, pp. 2514-2519, March 1999.	
	6	"Sgk Is an Aldosterone-induced Kianse in the Renal Collecting Duct" Aniko Naray-Fejes-Toth et al.; The Journal of Biological Chemistry 1999 vol. 274, No. 24, Issue of June 11 pp. 16973-16978, 1999.	
	7	"Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy" F. Lang et al.: July 5, 2000 vol. 97 no. 14 8157-8162	
	8	"Regulation of sgk by aldosterone and its effects on the epithelial Na+ channel" Alexander Shigaev et al. Am J Physiol Renal Physiol 278: F613-F619, 2000. Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel	
	9	Cellular Physiology and Biochemistry "Effects of the Serine/Threonine Kinase SGK1 on the Epithelial Na+-Channel (EnaC) and CFTR: Implications for Cystic Fibrosis" Carsten A. WAGNER et al. ; Cell Physiol Biochem 2001;11-209-218 .	
	10	"Serum-and Glucocorticoid-Regulated Kinase (SGK1) Gene and Blood Pressure" Andreas Busjahn, et al.; 2002 American Heart Association, Inc. pp. 256-260.	
	11	"Immediate-early Transcriptional Regulation and Rapid mRNA Turnover of a Putative Serine/Threonine Protein Kinase" Melanie K. Webster et al; The Journal of Biological Chemistry vol. 268, No. 16. Issue of June 5 pp. 11482-11485, 1993.	
	12	"Characterization of sgk, a Novel Member of the Serine/Threonine Protein Kinase Gene Family Which is Transcriptionally Induced by Glucocorticoids and Serum" Melanie K. Webster et al.; Molecular and Cellular Biology, Apr. 1993, pp. 2031-2040.	
	13	"The Regulation and Physiological Roles of Serum and Glucocorticoid-Induced Protein Kinase" Florian Lang et al.; Published 13 November 2001 pp.1-11.	
	14	"Serum and Glucocorticoid-Inducible Kinase (SGK) is a Target of the P1 3-Kinase-Stimulated signalling Pathway" Jongsun Park et al; The EMBO Journal vol. 18 no. 11 pp. 3024-3033, 1999.	
✓	15	"Rapid Upregulation of Serum and Glucocorticoid-Regulated Kinase (SGK) Gene Expression by Corticosteroids in Vivo" Francine E. Brennan et al.; Molecular and Cellular Endocrinology 166 (2000) 129-136.	

/Ian Dang/

07/24/2007

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

### Complete if Known

Application Number	10/516,745
Filing Date	December 4, 2004
First Named Inventor	Florian LANG et al.
Group Art Unit	Unknown 1647
Examiner Name	Unknown Ian Dang

Attorney Docket Number

RUFF-3

### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials * ↓	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.D./	16	"Expression of serum-and glucocorticoid-regulated kinase (sgk) mRNA is up-regulated by GM-CSF and other proinflammatory mediators in human granulocytes"; R.T. Cowling et al. Journal of Leukocyte Biology Vol. 67, February 2000.	
	17	"Activation of serum-and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositol 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2." Takayasu KOBAYASHI et al. Biochem J. (1999) 339:, 319-326	
	18	"Characterization of the structure and regulation of two novel isoforms of serum-and glucocorticoid-induced protein kinase" Takayasu KOBAYASHI et al. Biochem J. (1999) 344,, 189-197.	
	19	"Expression cloning and cDNA sequencing of the Na+/glucose co-transporter" Matthias A. Hediger et al.; Nature vol. 330 26 November 1987.	
↓	20	Cellular Physiology and Biochemistry 'The use of Xenopus laevis Oocytes for the Functional Characterization of Heterologously Expressed Membrane Proteins' Carsten A. Wagner et al. Cellular Physiol Biochem 2000; 10:1-12.	

Examiner Signature	/ian Dang/	Date Considered	07/24/2007
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete If Known **07/516745**

Application Number	<u>Unassigned</u> 10/516,745
Filing Date	December 6, 2004
First Named Inventor	Florian LANG et al.
Group Art Unit	<u>Unassigned</u> 1647
Examiner Name	<u>Unassigned</u> Ian Dang

Attorney Docket Number RUFF-3

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
/I.D./	1	4952567			August 28, 1990
/I.D./	2	2003055019			March 20, 2003

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Office <sup>3</sup>	Number <sup>4</sup>				
/I.D./	3	WO	0062781	Waldegger Siegfried	October 26, 2000		
	4	WO	9964062	Pharmacia & Up John AB	December 16, 1999		
	5	WO	8911295	Demeleys Pierre	November 30, 1989		Equiv to cite 1
↓	6	DE	4218669	Max-Planck-Gesellschaft	September 2, 1993		
	7	WO	0018918	Curagen Corp.	April 6, 2000		Equiv to cite 2

Examiner Signature	/ian Dang/	Date Considered	07/24/2007
--------------------	------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/516745

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	Unassigned 10/516,745
(use as many sheets as necessary)		Filing Date	December 6, 2004
		First Named Inventor	Florian LANG et al.
		Group Art Unit	Unassigned 1647
		Examiner Name	Unassigned Ian Dang
		Attorney Docket Number	RUFF-3
Sheet	2	of	2

## NON-PATENT LITERATURE DOCUMENTS

Examiner Signature	/Ian Dang/	Date Considered	07/24/2007
-----------------------	------------	--------------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.